Jim Simons Blueprint Medicines Corp Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Renaissance Technologies LLC holds 47,500 shares of BPMC stock, worth $5.06 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

47,500

Holding current value

$5.06 Million

% of portfolio

0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$73.17 - $99.79 $3.48 Million - $4.74 Million	47,500 New	47,500 $4.51 Million
Q4 2022 Feb 13, 2023	BUY	$41.06 - $66.48 $3.51 Million - $5.68 Million	85,400 New	85,400 $3.74 Million
Q2 2022 Aug 12, 2022	SELL	$45.23 - $70.15 $3.09 Million - $4.8 Million	-68,400 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$54.1 - $110.08 $3.7 Million - $7.53 Million	68,400 New	68,400 $4.37 Million
Q3 2021 Nov 12, 2021	SELL	$80.98 - $109.47 $12.3 Million - $16.7 Million	-152,374 Closed	0 $0

Q2 2021 Aug 13, 2021	SELL	$82.78 - $101.0 $3.89 Million - $4.75 Million	-47,026 Reduced 23.58%	152,374 $13.4 Million
Q1 2021 May 13, 2021	SELL	$90.71 - $108.28 $7.48 Million - $8.93 Million	-82,500 Reduced 29.27%	199,400 $19.4 Million
Q4 2020 Feb 10, 2021	BUY	$92.08 - $124.48 $8.9 Million - $12 Million	96,700 Added 52.21%	281,900 $31.6 Million
Q3 2020 Nov 13, 2020	BUY	$66.45 - $92.7 $8.34 Million - $11.6 Million	125,500 Added 210.22%	185,200 $17.2 Million
Q2 2020 Aug 13, 2020	SELL	$57.09 - $79.27 $2.83 Million - $3.92 Million	-49,500 Reduced 45.33%	59,700 $4.66 Million
Q1 2020 May 14, 2020	BUY	$48.11 - $82.22 $5.25 Million - $8.98 Million	109,200 New	109,200 $6.39 Million

Others Institutions Holding BPMC

# of Institutions

314

Shares Held

60.6M

Call Options Held

634K

Put Options Held

691K

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.36B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account